Truist Securities analyst Kaila Krum maintains Aziyo Biologics (NASDAQ:AZYO) with a Buy and raises the price target from $8 to $10.
November 15, 7:41 AM
Piper Sandler analyst Matt O'Brien maintains Aziyo Biologics (NASDAQ:AZYO) with a Overweight and raises the price target from $9 to $10.5.
May 9, 4:49 PM
Guidance for Full Year 2022 Aziyo is confirming its expectation that total net sales for the full year 2022 will range between $47 to $50 million. Excluding approximately $4.9 million of FiberCel sales in 2021, this
May 6, 10:06 AM
Aziyo Biologics (NASDAQ:AZYO) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that Aziyo Biologics will report an earnings per share (EPS) of $-0.62.
March 4, 10:28 AM
Aziyo Biologics Inc (NASDAQ:AZYO) Q4 FY21 sales decreased 13% to $10.9 million, missing the consensus of $11.06 million. Excluding the contribution…